Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses (10 to 50 mg) of BI 44370 BS Solution in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Phase I)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs BI 44370 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Aug 2014 New trial record